In Vitro Activity of Tebipenem against Various Resistant Subsets of Escherichia coli Causing Urinary Tract Infections in the United States (2018 to 2020)

This study investigated the activity of an oral carbapenem, tebipenem, against various molecularly characterized subsets of Escherichia coll. A total of 15.0% of E. coli isolates (360/2,035 isolates) met the MIC criteria for screening for beta-lactamases. Most of those isolates (74.7% [269/360 isolates]) carried bla(CTX-M). The CTX-M distribution varied (50% to 86%) among Census Regions, as did that of plasmid AmpC genes (up to 41% among E. coli isolates from the New England Region). Tebipenem and intravenous carbapenems showed uniform activity against various E. coli subsets.